Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Equity Average (2016 - 2026)

Standard Biotools has reported Equity Average over the past 15 years, most recently at $412.0 million for Q4 2025.

  • Quarterly Equity Average fell 14.27% to $412.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $412.0 million through Dec 2025, down 14.27% year-over-year, with the annual reading at $448.0 million for FY2025, 176.83% up from the prior year.
  • Equity Average was $412.0 million for Q4 2025 at Standard Biotools, roughly flat from $412.1 million in the prior quarter.
  • Over five years, Equity Average peaked at $543.8 million in Q2 2024 and troughed at -$139.9 million in Q4 2023.
  • The 5-year median for Equity Average is $110.3 million (2021), against an average of $169.3 million.
  • Year-over-year, Equity Average crashed 1272.4% in 2023 and then skyrocketed 616.57% in 2024.
  • A 5-year view of Equity Average shows it stood at $97.0 million in 2021, then plummeted by 174.36% to -$72.1 million in 2022, then tumbled by 94.0% to -$139.9 million in 2023, then soared by 443.51% to $480.5 million in 2024, then decreased by 14.27% to $412.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Equity Average are $412.0 million (Q4 2025), $412.1 million (Q3 2025), and $439.6 million (Q2 2025).